Patient & Visitor InformationContact Us
  • Publications

  • Opal SM, Laterre P-F, Francois B, LaRosa SP, Angus DC, Mira J-P, Wittebole X, Dugenier T, Parrotin D, Tidswell M, Tillis T, Jaurequi A, Krell E, Pachl Y, Takahashi H, Peckelsen A, Cordasco D, Chang C, Oeye E, Aikawa N, Maruyama T, Schein R, Kalil A, Van Nuffelen M, Lynn M, Rossignol D, Gogate J, Roberts M, Wheeler J, Vincent J-L, and the ACCESS Study Group: Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized study. Journal of the American Medical Association 2013;309(11): 1154-1162.

    Dellinger P, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Servansky J, Sprung CL, Douglas IS, Jaeschke R, Osborn T, Nunnally M, Townshead SR, Reinhart K, Kleinpell R, Angus D, Deutschman CS, Machado F, Rubenfeld, G, Webb S, Beale R J, Vincent J-L, Moreno R, for the surviving sepsis campaign guidelines committee. The surviving sepsis guidelines: 2012. Critical Care Medicine 2013;41(2):580-637.

    Fedson D, Opal SM. The continuing controversy over H5N1 influenza virus transmissibility research: An opportunity for a practical response to a global threat. Influenza and Respiratory Viruses 2013; 9(5):1-10.

    Opal SM. Immunologic alterations and the pathogenesis of organ failure in the ICU. Semin Resp Crit Care Med 2011;32(5): 599-580.

    Opal SM, Lim, Y-P, Cristofaro P, Artenstein A, Kessimian N, Palardy JE, Delsesto D, Parejo N. Siryaporn E. Inter-alpha inhibitor proteins as a novel treatment strategy of systemic anthrax infection. Shock 2011; 35(1):42-44.